CancerVax Successfully Demonstrates Full Nanoparticle Delivery in Mouse Study

▤ Summary

CancerVax reports successful mouse biodistribution results for its complete cancer-targeting lipid nanoparticle. The company says the Marker1+Marker2 design reduced healthy tissue exposure and showed lower liver stress than conventional LNPs. It also says the construct delivered the Smart mRNA payload as intended and maintained spleen uptake to support immune priming. The milestone moves the company further into preclinical efficacy studies and toward defining a therapeutic window for its platform.

▦ Linked Companies